| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 0.0 |
| Net income | -14.6 | -2.9 |
| EPS (diluted, $ a share) | $-0.07 | $-0.38 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: PALI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Palisade Bio, Inc.: key numbers
- Share price
- $1.03Close, Nov 16
- Market cap
- $185M
- Shares outstanding
- 179.28MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Palisade Bio, Inc.
All →Palisade Bio Financial Results
Palisade Bio reported third quarter 2026 financial results and provided a clinical update on its PALI-2108 programs, including the initiation of the Phase 2b ASCENTRA-UC trial. The company ended the quarter with $113.6 million in cash and expects topline results from the UC trial in Q4 2027.
“ASCENTRA-UC is now underway, and our focus is on driving enrollment and executing the study to deliver topline results in the fourth quarter of 2027. With nearly all planned U.S. sites activated, we are expanding our global clinical footprint to build on that progress.”
JD Finley, Chief Executive Officer of Palisade Bio
“In parallel, we are preparing to initiate ASCENTRA-CD, with initiation of enrollment targeted for the first quarter of 2027. Our strong financial position supports execution across both programs as we work to establish PALI-2108’s potential as a differentiated, once-daily oral treatment for patients living with IBD.”
JD Finley, Chief Executive Officer of Palisade Bio
Palisade Bio Insider Donald Allen Williams Buys $28.8K of Stock
Donald Allen Williams bought 20,000 shares of Palisade Bio, Inc. at $1.42 to $1.46 a share (average $1.44) in 2 transactions, worth $28.8K in total between Oct 1, 2026 and Oct 2, 2026. Shares held after the trade: 1,590,294 (+0.6%).
- Value
- $28.8K
- Shares
- 20,000
- Average price
- $1.44
- Holding change
- +0.6%
- Trade date
- Oct 1, 2026 to Oct 2, 2026